L3VLUP
ProSign in

TXG · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TXGVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TXG
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterTXGVRTX
Q3 202017 holders, $1.8bn31 holders, $21.9bn
Q4 202014 holders, $1.9bn30 holders, $18.4bn
Q1 202110 holders, $3.0bn31 holders, $15.4bn
Q2 20218 holders, $3.7bn30 holders, $12.7bn
Q3 20217 holders, $2.6bn35 holders, $10.1bn
Q4 20217 holders, $2.9bn28 holders, $12.4bn
Q1 20225 holders, $849m23 holders, $16.1bn
Q2 20225 holders, $642m25 holders, $18.1bn
Q3 20225 holders, $425m22 holders, $18.4bn
Q4 20226 holders, $546m28 holders, $18.4bn
Q1 202310 holders, $995m26 holders, $21.4bn
Q2 202311 holders, $1.4bn27 holders, $24.7bn
Q3 202312 holders, $1.3bn33 holders, $24.3bn
Q4 20239 holders, $1.7bn32 holders, $28.6bn
Q1 202410 holders, $1.2bn31 holders, $29.8bn
Q2 20246 holders, $289m29 holders, $33.4bn
Q3 20247 holders, $337m27 holders, $33.5bn
Q4 20246 holders, $247m26 holders, $28.5bn
Q1 20257 holders, $165m21 holders, $35.4bn
Q2 20258 holders, $231m21 holders, $32.3bn
Q3 20256 holders, $187m22 holders, $25.9bn
Q4 20255 holders, $272m26 holders, $31.8bn
Q1 20262 holders, $259m25 holders, $31.8bn
Q2 20265 holders, $1.2bn26 holders, $34.6bn
TXG

10X Genomics Inc

Holders
10
Reported value
$1.2bn
Buyers
7
Sellers
2

Breadth +5 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
31
Reported value
$29.8bn
Buyers
16
Sellers
19

Breadth -3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 34 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TXG (3)

Baillie Gifford & Co, Quantbot Technologies LP, Woodline Partners LP

Only VRTX (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →